Abstracts from 2014 through the most recent CROI can be viewed in this searchable database once they have been presented at the conference. Abstract Contents: The searchable database includes abstract text as submitted by the authors prior to CROI. Study data might be updated during the presentation at CROI. Please refer to the electronic poster or webcast for updates. Searching the Abstract Database: Enter the criteria below and click the “Search” button. After the search has been entered, the results will appear below the search form.

CROI conference materials (eg, the conference program, Abstract eBook, electronic posters, CROI logo, etc) are protected by copyright. Permission to replicate or reproduce these elements, in whole or in part, must be obtained from the CROI Conference Manager, the International Antiviral Society-USA (IAS-USA). Study data (including figures within abstracts or electronic posters) are the property of the study authors. Permission to use data and figures cannot be given by IAS–USA unless it is for regulatory reasons. For more information, please email CROIabstracts@iasusa.org.

Search Results

1277 Results

928 – In Vitro Modeling of the Effects of Impaired HDL on Atherogenesis in Long COVID Syndrome

Background The mechanisms that drive SARS-CoV-2-related cardiovascular complications of Long COVID (PASC) such as atherosclerotic cardiovascular disease (CVD) remain unclear. Prior studies have shown alterations of HDL function in infections and SARS-CoV-2 infection, persistent oxidative stress, lipid abnormalities and macrophage dysfunction post COVID-19 that may contribute to HDL dysfunction and CVD. However, the effect of…

917 – Higher Mortality Following SARS-CoV-2 Infection in Rural Dwellers Persists 2 Years After Infection

Background Rural regions in the U.S. have unique health challenges, including higher socioeconomic inequalities, greater comorbidity prevalence, and limited healthcare access. Previous work has demonstrated that these challenges extend to COVID-19, with rural residents having worse acute outcomes after SARS-CoV-2 infection. However, the longer-term impact of COVID-19 on rural residents remains uncertain. This study analyzed…

938 – Exploring the Molecular Pathways of Long COVID With Post-Exertional Fatigue: A Multiomic Approach

Background Post-exertional malaise (PEM) is a disabling condition characterized by worsened symptoms after mental or physical exertion, commonly seen in Long-COVID (LC). While its underlying pathophysiology is unclear, potential mechanisms include oxidative stress, and metabolic derangements. We conducted a multiomic analysis to identify changes in energy metabolism, immune function and cellular stress responses in patients with…

925 – A Population-Based Study of Functional Disability, COVID-19 Symptoms, and Long COVID Among US Adults

Background COVID-19 can have long-term effects on health. People with disabilities may bear a heavier burden of COVID-19 and be more susceptible to severe and prolonged symptoms. This study assessed relationships between functional disability, COVID-19 symptoms, and long COVID in US adults. Methods We obtained population-based data from the 2022 National Health Interview Survey using…

716 – Tracking Key Remdesivir Resistance Mutations in SARS-CoV-2 Using GISAID Data (2020-2024)

Background The emergence of remdesivir (RDV) resistance mutations poses a potential challenge in treating SARS-CoV-2 infections, especially as the virus continues to evolve globally. GISAID data provides an extensive resource for tracking such mutations. This study aims to investigate the temporal trends and incidence rates of RDV resistance-associated mutations, specifically those conferring a >2.5-fold reduction…

923 – Completeness of COVID-19 Outcomes Among People With HIV Receiving Care in New York City in 2020

Background Many early COVID-19 outcome studies were based exclusively on electronic health record (EHR) data from single health systems. However, many people in 2020 who would have ordinarily received care in the same system experienced outcomes at other hospitals or at home – 2 common scenarios when COVID-19 temporarily transformed usual practice. We assessed completeness…

931 – Immune and Virologic Trajectories 1.5 Years Before and After COVID-19 in an Early-Treated HIV Cohort

Background SARS-CoV-2 infection can be associated with immunologic dysfunction and might serve as a ‘second hit’ to immune function in people with HIV (PWH) despite suppression with antiretroviral therapy (ART). We leveraged the RV254 Thai cohort to examine the trajectory of immunologic and virologic parameters 1.5 years pre- and post-COVID-19 in PWH on stable ART initiated…

932 – Longitudinal Changes in Arterial Stiffness and Inflammation From Pre- to Post-COVID-19 Infection

Background We have previously shown in cross-sectional studies that COVID-19 infection was associated with arterial stiffness and increased oxidized LDL (oxLDL).  In this study, we assess changes in these cardiovascular parameters after COVID infection in a group of individuals who have documented pre-COVID assessments.  Having pre-COVID assessments has been a limitation of current studies. Methods…

944 – Novel Plasma Biomarkers for the Detection of Long COVID Defined by Multiapproach Analysis

Background Long COVID (LC) is a newly defined syndrome linking COVID infection with an umbrella of long-lasting symptoms. Due to this variety of presentation and lack of understanding of the mechanism involved, no reliable biomarkers have been found so far, and diagnostic uncertainty remains high. In the prospect of personalized medicine, there is a dire…

900 – In Vitro Modulation of Adipocyte Differentiation by TAF/TDF After Challenge With New ARV Regimens

Background We previously demonstrated in a 3T3L1cells in vitro model of adipogenesis, that Integrase Strand Transfer Inhibitors (INSTI) increase adipogenesis, while, tenofovir alafenamide fumarate (TAF) and tenofovir disoproxil fumarate (TDF), displayed an inhibitory effect, counteracting increased adipogenesis caused by INSTIs [dolutegravir (DTG), bictegravir (BIC)]. Deregulation of the expression levels of two families of adipocyte differentiation transcription factors, the CCAAT/enhancer-binding proteins (C/EBPs) and the…